Tag: MindMed - Psilocybin Alpha

New Resource: Psychedelics Drug Development Tracker

MindMed Announces Chief Executive Officer Transition

MindMed Announces Chief Executive Officer Transition

Post published:June 9, 2021
Post category:Press Release

MindMed announces shareholder Meeting Results

MindMed announces shareholder Meeting Results

Post published:May 27, 2021
Post category:Press Release

MindMed and Liechti Lab in Basel Switzerland Publish First Pharmacogenetic Data on LSD to Help Guide Personalized Dosing

MindMed and Liechti Lab in Basel Switzerland Publish First Pharmacogenetic Data on LSD to Help Guide Personalized Dosing

Post published:May 26, 2021
Post category:Press Release

MindMed Announces Launch of Collaboration with Nextage Therapeutics’ Brain Targeting Liposome System

MindMed Announces Launch of Collaboration with Nextage Therapeutics’ Brain Targeting Liposome System

Post published:May 24, 2021
Post category:Press Release

MindMed Announces the Approval of Mescaline Study

MindMed Announces the Approval of Mescaline Study

Post published:May 20, 2021
Post category:Press Release

The Chopra Foundation and MindMed Enter Into Letter of Intent to Partner on the Future of Psychedelic Medicines & Mental Wellbeing

The Chopra Foundation and MindMed Enter Into Letter of Intent to Partner on the Future of Psychedelic Medicines & Mental Wellbeing

Post published:May 18, 2021
Post category:Press Release

MindMed Receives FDA Type C Meeting Response for Project Lucy Phase 2b Clinical Trial

MindMed Receives FDA Type C Meeting Response for Project Lucy Phase 2b Clinical Trial

Post published:May 17, 2021
Post category:Press Release

MindMed Announces 2021 Q1 Financial Results; Cash Balance of $160m USD ($194m CAD) to Execute on Diverse Clinical Pipeline

MindMed Announces 2021 Q1 Financial Results; Cash Balance of $160m USD ($194m CAD) to Execute on Diverse Clinical Pipeline

Post published:May 14, 2021
Post category:Press Release

MindMed Announces Appointment of Dr. Sarah Y. Vinson as Additional Director

MindMed Announces Appointment of Dr. Sarah Y. Vinson as Additional Director

Post published:May 14, 2021
Post category:Press Release

MindMed Bolsters Management Team, Appoints Peter Mack PhD as Vice President of Pharmaceutical Development

MindMed Bolsters Management Team, Appoints Peter Mack PhD as Vice President of Pharmaceutical Development

Post published:May 13, 2021
Post category:Press Release

End of content

No more pages to load

Psilocybin Alpha

The definitive resource for investors in the emergent psychedelic medicine sector. Cut through the shroom stock noise with exclusive news, interviews, data and private financing opportunities.

Quick Links

Newsletter

Industry insights and interviews delivered to your inbox. No spam, just valuable information.